• Home
  •  / Corindus Vascular Robotics

Corindus Vascular Robotics

OverviewSuggest Edit

Corindus Vascular Robotics is a global technology leader in robotic-assisted vascular interventions. The Company's CorPath® System is the first FDA-cleared medical device to bring robotic-assisted precision to radial, coronary and peripheral procedures.

With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures.
Corindus recently strengthened its operational and clinical teams to support an expansion of the FDA-cleared CorPath GRX System and its commitment to conducting cutting-edge vascular robotics research. 

TypePublic
Founded2002
HQWaltham, MA, USMap
Websitecorindus.com
Employee Ratings4.3More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2019)90(-15%)
Revenue (FY, 2018)$10.8 M(+12%)
Share Price (Nov 2019)$4.3
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Corindus Vascular Robotics

Aquilla S. Turk

Aquilla S. Turk

Chief Medical Officer, Neuroendovascular

Corindus Vascular Robotics Office Locations

Corindus Vascular Robotics has an office in Waltham
Waltham, MA, US (HQ)
309 Waverley Oaks Rd
Show all (1)

Corindus Vascular Robotics Financials and Metrics

Corindus Vascular Robotics Revenue

Embed Graph
View revenue for all periods
Corindus Vascular Robotics's revenue was reported to be $10.78 m in FY, 2018
USD

Revenue (Q2, 2019)

4.6m

Gross profit (Q2, 2019)

1.8m

Gross profit margin (Q2, 2019), %

39.3%

Net income (Q2, 2019)

(10.7m)

EBIT (Q2, 2019)

(10.3m)

Market capitalization (29-Oct-2019)

891.1m

Closing stock price (29-Oct-2019)

4.3

Cash (30-Jun-2019)

31.9m

EV

873.5m
Corindus Vascular Robotics's current market capitalization is $891.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

175.8k36.0k2.7m2.8m9.7m10.8m

Cost of goods sold

212.4k57.7k3.7m5.0m9.3m8.7m

Gross profit

(36.6k)(21.7k)(995.0k)(2.2m)385.0k2.1m

Gross profit Margin, %

(21%)(60%)(36%)(77%)4%20%
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

54.7k9.1k19.4k3.9k4.1k554.0k776.0k909.0k212.0k1.1m508.0k688.0k777.0k2.3m2.4m1.5m1.7m3.0m3.0m4.6m

Cost of goods sold

62.7k28.4k19.4k5.8k4.7k793.0k801.0k941.0k722.0k1.1m1.1m1.2m1.9m2.2m2.2m1.9m2.2m1.8m2.4m2.8m

Gross profit

(8.0k)(19.3k)26.0(1.9k)(635.0)(239.0k)(25.0k)(32.0k)(510.0k)30.0k(606.0k)(532.0k)(1.1m)58.0k242.0k(444.0k)(486.0k)1.1m622.0k1.8m

Gross profit Margin, %

(15%)(213%)0%(50%)(15%)(43%)(3%)(4%)(241%)3%(119%)(77%)(144%)3%10%(30%)(29%)38%20%39%
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

87.022.1m17.5m23.8m

Accounts Receivable

40.7k700.0878.0k2.9m4.6m

Prepaid Expenses

312.0591.0k539.0k447.0k

Inventories

1.3m2.1m2.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

3.3k249.2k29.5m22.0m58.9m29.7m23.6m21.4m18.1m45.2m35.2m26.2m44.0m34.3m29.6m37.8m31.9m

Accounts Receivable

22.4k1.3k350.02.6k477.0k222.0k527.0k566.0k1.3m131.0k531.0k396.0k442.0k1.3m2.0m1.8m2.6m3.9m4.8m

Prepaid Expenses

950.0647.0k532.0k536.0k944.0k352.0k406.0k305.0k396.0k430.0k313.0k694.0k806.0k923.0k1.0m1.1m

Inventories

2.0m1.6m1.6m1.6m1.5m1.6m1.6m2.4m2.6m2.8m3.0m2.8m2.7m1.9m1.8m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(189.8k)(267.5k)(28.8m)(33.1m)(34.1m)(35.0m)

Depreciation and Amortization

9.0k9.0k706.0k725.0k723.0k853.0k

Inventories

(346.0k)(216.0k)(1.6m)(1.0m)

Accounts Payable

1.7k(3.6k)(380.0k)1.5m1.8m689.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(111.8k)(101.7k)(161.7k)(213.6k)(64.1k)(18.0m)(7.2m)(14.5m)(21.5m)(7.6m)(15.2m)(23.3m)(9.9m)(18.3m)(26.2m)(10.0m)(20.0m)(27.6m)(9.7m)(20.3m)

Depreciation and Amortization

6.7k2.2k4.5k6.7k2.2k508.0k166.0k330.0k510.0k209.0k387.0k564.0k175.0k368.0k532.0k163.0k331.0k509.0k193.0k398.0k

Inventories

230.0k(213.0k)(219.0k)(456.0k)(136.0k)(238.0k)(290.0k)(1.2m)(1.6m)(2.0m)(1.3m)(1.4m)(1.2m)531.0k569.0k

Accounts Payable

1.4k(2.4k)(3.6k)19.9k1.5m449.0k(550.0k)(441.0k)919.0k152.0k659.0k(316.0k)(173.0k)684.0k(309.0k)(698.0k)(969.0k)(1.0m)1.1m
show all
USDQ3, 2013

Financial Leverage

-1 x
Show all financial metrics

Corindus Vascular Robotics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

Learn more about our premium products
SecurityScorecard logo

Corindus Vascular Robotics Online and Social Media Presence

Corindus Vascular Robotics's Trends

Embed Graph

Corindus Vascular Robotics News and Updates

October 31, 2019

Cadwalader Advises Corindus Vascular Robotics on Acquisition by Siemens Healthineers AG

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures.read more
August 08, 2019

SHAREHOLDER ALERT: WeissLaw LLP Investigates Corindus Vascular Robotics, Inc.

NEW YORK, Aug. 8, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Corindus Vascular Robotics, Inc. ("Corindus" or the "Company") (NYSE: CVRS) in connection with the proposed acquisition of the...
August 08, 2019

Corindus Vascular Robotics stock rockets on heavy volume after $1.1 billion buyout deal

Shares of Corindus Vascular Robotics Inc. rocketed 76% toward a 4-year high in very active premarket trading Thursday, after the robotic-assisted vascular interventions company agreed to be acquired in a deal valued at $1.1 billion by Siemens Healthineers AG. Trading volume spiked to 14.8 million s…
May 11, 2018

Corindus Vascular Robotics' (CVRS) CEO Mark Toland on Q1 2018 Results - Earnings Call Transcript

Corindus Vascular Robotics Blogs

December 22, 2021

Remote PCI treatment, expansion into neurovascular care highlight 2022 projects

    The evolutionary path of our CorPath® GRX is approaching several major milestones in 2022 that mark the next steps in our mission to revolutionize interventional treatment and expand access to care. The demand for innovative and transformative technology has never been greater and we are poise…
October 21, 2021

The Evolution of Medical Robotics and Predictions for the Next Generation

The iteration of robotic platforms that healthcare providers use today, such as CorPath® GRX, are fairly new technologies, but the ideas and motivations that spurred their development have been intrinsic to medicine for more than a century. Providers have long searched for ways to improve the qualit…
May 20, 2021

Record investments in technology will spur innovative patient care

Healthcare providers around the world have set out on a mission to achieve one thing: predictability. In the aftermath of a pandemic that has been anything but predictable, every stakeholder in the healthcare continuum has a vested interest in making it easier to predict positive patient outcomes.
April 26, 2021

Opportunities for Women in Cardiology: Insights from Our CorPath GRX Users

Several of our female CorPath® GRX users from across the globe have contributed to the American College of Cardiology’s Women in Cardiology section. Featured prominently in the “#ChooseCardiology” column, each of the physicians discusses their path to interventional cardiology and the role that robo…
March 18, 2021

Corindus sets up shop at Orsi Academy in Belgium

About an hour outside of Brussels sits a state-of-the-art innovation center that is an ideal venue for Corindus to demonstrate its CorPath® GRX robot to interventionalists and catheterization laboratory staff. In 2010, Dr. Alexandre Mottrie, a pioneer in robotic surgery, founded the O.L.V. Vattikuti…
September 15, 2020

Telerobotic procedures featured in new Verizon documentary, “Speed of Thought”

In October 2019, Dr. Ryan Madder sat in front of a control panel in Waltham, MA, preparing for a robotic-assisted percutaneous coronary intervention (PCI) as he has done on countless occasions. Beyond the familiarity of the robotic controls and monitor with fluoroscopic images of the heart, this was…
Show more

 Corindus Vascular Robotics Frequently Asked Questions

  • When was Corindus Vascular Robotics founded?

    Corindus Vascular Robotics was founded in 2002.

  • Who are Corindus Vascular Robotics key executives?

    Corindus Vascular Robotics's key executives are Aquilla S. Turk.

  • How many employees does Corindus Vascular Robotics have?

    Corindus Vascular Robotics has 90 employees.

  • What is Corindus Vascular Robotics revenue?

    Latest Corindus Vascular Robotics annual revenue is $10.8 m.

  • What is Corindus Vascular Robotics revenue per employee?

    Latest Corindus Vascular Robotics revenue per employee is $119.8 k.

  • Who are Corindus Vascular Robotics competitors?

    Competitors of Corindus Vascular Robotics include Distalmotion, Restoration Robotics and OrthoSpin.

  • Where is Corindus Vascular Robotics headquarters?

    Corindus Vascular Robotics headquarters is located at 309 Waverley Oaks Rd, Waltham.

  • Where are Corindus Vascular Robotics offices?

    Corindus Vascular Robotics has an office in Waltham.

  • How many offices does Corindus Vascular Robotics have?

    Corindus Vascular Robotics has 1 office.